Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs
Carlo Patrono, … , Paola Patrignani, Luis A. García Rodríguez
Carlo Patrono, … , Paola Patrignani, Luis A. García Rodríguez
Published July 1, 2001
Citation Information: J Clin Invest. 2001;108(1):7-13. https://doi.org/10.1172/JCI13418.
View: Text | PDF
Perspective

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

  • Text
  • PDF
Abstract

Authors

Carlo Patrono, Paola Patrignani, Luis A. García Rodríguez

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Determinants and sources of variability in GI complications of COX-inhib...
Determinants and sources of variability in GI complications of COX-inhibitory drugs. (a) Major determinants of the likelihood of an upper GI bleeding (UGIB) complication resulting from administration of a COX inhibitor include pharmacokinetic (PK) and pharmacodynamic (PD) variables, as well as the interaction of the drug with pre-existing risk factors for UGIB. PK features, such as half-life of the drug, and PD features, such as its selectivity for the COX-2 isoform, are intrinsic to the COX inhibitor. The presence or absence of risk factors for UGIB will clearly vary between patients. Significant interindividual variability arises from several sources, as shown in b and c, and is superimposed on each of these effects. Modified from ref. 2. (b) In addition to the variable plasma levels achieved after oral dosing of a COX inhibitor, the inhibition of the platelet COX-1 isozyme (circles) and the monocyte COX-2 isozyme (triangles) in response to any given plasma level of the inhibitor is highly variable between subjects. COX-isozyme inhibition, measured ex vivo, is plotted as a function of plasma meloxicam levels in individual subjects. Modified from ref. 31. (c) The variable excess of UGIB induced by NSAIDs as a function of the increasing severity of prior history: 1, none; 2, dyspepsia; 3, gastritis; 4, uncomplicated ulcer; 5, complicated ulcer. Within each cohort of subjects, UGIB rates for individuals currently using NSAIDs (triangles) exceed those for non-users (circles), but the effect of prior history greatly amplifies that of NSAID use (data from ref. 20).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts